Company: RCUS
Filing Date: 2025-04-22
Form Type: DEF 14A
Source: 0001724521-25-000052
Chunk: 46

Company: Arcus Biosciences, Inc.
Filing Date: 2025-04-22
Form: DEF 14A
Chunk 46
---
• Geography : geographically situated in a biotechnology hub within the U.S., with a preference for those located in Northern California.

Following this review, the Compensation Committee approved thepeer group set forth below to help set executive compensation for our fiscal year 2024, which differed from the prior year peer group as BridgeBio Pharma, Inc., Day One Biopharmaceuticals, Inc. and ImmunityBio, Inc. were added and Apellis Pharmaceuticals, Inc., Fate Therapeutics Inc., ImmunoGen, Inc. and Revance Therapeutics Inc. were removed. The changes to our peer group from the prior year are largely due to changes in stage of development and market capitalization.

| Agios Pharmaceuticals Inc.       |     | Alector, Inc.                  |     | Allogene Therapeutics, Inc.   |
| Arrowhead Pharmaceutics, Inc.    |     | BridgeBio Pharma, Inc.         |     | Cytokinetics, Incorporated    |
| Day One Biopharmaceuticals, Inc. |     | Denali Therapeutics Inc.       |     | Editas Medicine, Inc.         |
| ImmunityBio, Inc.                |     | Intella Therapeutics Inc.      |     | Iovance Biotherapeutics, Inc. |
| Kura Oncology, Inc.              |     | Mirati Therapeutics, Inc.      |     | Prothena Corporation Plc      |
| REGENXBIO Inc.                   |     | SpringWorks Therapeutics, Inc. |     | Syndax Pharmaceuticals Inc.   |
| Xencor Inc.                      |     |                                |     |                               |

#### Elements of Compensation
Our executive compensation program generally consists of three principal components:

• base salary;

• short-term incentives in the form of an annual cash bonus opportunity; and

• long-term incentives in the form of equity incentive awards (stock options and RSUs).

As part of our pay-for-performance philosophy, a substantial portion of executive compensation is variable and at risk. However, we do not have any formal policies for allocating compensation among salary, cash bonus opportunity and equity incentives, or among cash and non-cash compensation. Instead, the Compensation Committee uses its judgment to establish a total compensation program for each executive officer that it believes is appropriate to achieve the goals of our executive compensation program and our corporate objectives.

Base Salary

Base salary is intended to provide financial security through a fixed amount of cash compensation to compensate our executive officers for performing their day-to-day duties and